Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…
Read this Press Release: Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare ConferencePoxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…
Read this Press Release: Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019Poxel Announces Fourth Quarter and Full Year 2018 Financial Update
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…
Read this Press Release: Poxel Announces Fourth Quarter and Full Year 2018 Financial Update
